A Study to Evaluate Single and Multiple Doses of TLC-6740 in Healthy Subjects

Study Overview
=================
Brief Summary
-----------------
This phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TLC-6740 after single- and multiple-ascending doses in healthy subjects.

Detailed Description
-----------------
The primary objectives are to assess the safety, tolerability, and plasma PK of TLC-6740 in healthy subjects. The exploratory objective is to evaluate the PD of TLC-6740 in healthy subjects. This study is comprised of four parts: Part A (single-ascending dose), Part B (multiple-ascending dose), optional Part C (adaptive single- and/or multiple-ascending dose), and Part D (relative bioavailability of a tablet formulation of TLC-6740). Up to 48, 50, 50, and 8 healthy subjects will be recruited in Parts A, B, C, and D, respectively. The effect of food on TLC-6740 PK will also be evaluated in this study.

Official Title
-----------------
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of TLC-6740 in Healthy Subjects and an Open-Label Assessment of the Relative Bioavailability of, and Effect of Food on, a Tablet Formulation of TLC-6740

Conditions
-----------------
Healthy Subjects

Intervention / Treatment
-----------------
* Drug: TLC-6740 Oral Solution
* Other: Placebo
* Drug: TLC-6740 Tablet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Non-smoking, healthy male or female subject between 18 and 55 years of age, inclusive Body mass index from 19 to 35 kg/m2, inclusive Estimated glomerular filtration rate ≥ 80 mL/min Normal liver biochemistry tests Screening laboratory evaluations (hematology, chemistry, and urinalysis) must fall within the normal range of the local laboratory's reference ranges unless the results have been determined by the investigator to have no clinical significance Subject must have either a normal 12-lead electrocardiogram (ECG) or one with abnormalities that are considered clinically insignificant by the investigator Females of childbearing potential must have a negative pregnancy test at Screening and clinic admission Male subjects and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception Must, in the opinion of the investigator, be in good health based upon medical history and physical examination, including vital signs Exclusion Criteria: Pregnant or lactating subjects Subjects who have any serious or active medical or psychiatric illness (including depression) that, in the opinion of the investigator, would interfere with the subject's treatment, assessment, or compliance with the protocol Subjects who have received any investigational compound within 30 days or 5 half-lives, whichever is longer, prior to study drug dosing Current alcohol abuse that is judged by the investigator to potentially interfere with the subject's compliance or safety Current substance abuse that is judged by the investigator to potentially interfere with the subject's compliance or safety A positive test result for human immunodeficiency virus (HIV-1) antibody, hepatitis B (HBV) surface antigen, or hepatitis C (HCV) antibody Subjects who have taken any prescription medications or over-the-counter medications, including herbal products, within 28 days prior to start of study drug dosing, with the exception of vitamins, acetaminophen (paracetamol), ibuprofen, and/or hormonal contraceptive medications Subjects who have been treated with systemic steroids, immunosuppressant therapies, or chemotherapeutic agents within 3 months prior to Screening or expected to receive these agents during the study (e.g., corticosteroids, immunoglobulins, and other immune- or cytokine-based therapies) Medical history of serious skin disease in the opinion of the investigator, such as but not limited to rash, food allergy, eczema, psoriasis, or urticaria Medical history of drug sensitivity or drug allergy (such as anaphylaxis or hepatoxicity) Presence or history of cardiovascular disease, including significant cardiovascular disease (including a history of myocardial infarction based on ECG and/or clinical history), history of cardiac conduction abnormalities (including any history of ventricular tachycardia), congestive heart failure, cardiomyopathy with left ventricular ejection fraction < 40%, a family history of Long QT Syndrome, or unexplained death in an otherwise healthy individual between the ages of 1 and 30 years Syncope, palpitations, or unexplained dizziness Implanted defibrillator or pacemaker Medical history of liver disease, including but not limited to alcoholic liver disease, autoimmune disorders (e.g., primary biliary cholangitis, primary sclerosing cholangitis, autoimmune hepatitis), drug-induced hepatotoxicity, Wilson disease, clinically significant iron overload, or alpha-1-antitrypsin deficiency) History of rhabdomyolysis Severe peptic ulcer disease, gastroesophageal reflux disease, or other gastric acid hypersecretory conditions History of medical or surgical treatment that permanently alters intestinal absorption (e.g., gastric or intestinal surgery) Subjects who have received vaccination for COVID-19 within 14 days of Admission Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Sequential Assignment
Interventional Model Description: This study consists of four parts: Part A (single-ascending dose), Part B (multiple-ascending dose), optional Part C (adaptive single- and/or multiple-ascending dose), and Part D (relative bioavailability of a tablet formulation of TLC-6740).
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Oral Solution<br>Oral solution of TLC-6740 | Drug: TLC-6740 Oral Solution<br>* Oral solution of TLC-6740<br>|
| Placebo Comparator: Placebo<br>Oral dose of placebo-to-match | Other: Placebo<br>* Placebo-to-match<br>|
| Experimental: Tablet<br>Tablet formulation of TLC-6740 | Drug: TLC-6740 Tablet<br>* Tablet formulation of TLC-6740<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of TLC-6740 treatment-emergent adverse events | Adverse events (AEs) - severity of the AEs will be graded using the Common Terminology Criteria for AE (CTCAE) (v5.0). The relationship between AEs and the study drug will be indicated as related or not related. | Through study completion, up to Day 24 of the study | 
| PK of TLC-6740 AUC | Area under the concentration-time curve | Through study completion, up to Day 24 of the study | 
| PK of TLC-6740 Cmax | Maximum plasma concentration | Through study completion, up to Day 24 of the study | 
| PK of TLC-6740 tmax | Time to reach Cmax | Through study completion, up to Day 24 of the study | 
| PK of TLC-6740 t1/2 | Half-life | Through study completion, up to Day 24 of the study | 
| PK of TLC-6740 CL/F | Apparent clearance, calculated as dose/AUC0-inf | Through study completion, up to Day 24 of the study |